Vanguard Group Inc. Buys 107,846 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Vanguard Group Inc. raised its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 1.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,253,936 shares of the company’s stock after buying an additional 107,846 shares during the period. Vanguard Group Inc. owned 0.06% of Arcutis Biotherapeutics worth $210,654,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Johnson Investment Counsel Inc. bought a new position in Arcutis Biotherapeutics during the third quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Arcutis Biotherapeutics by 28.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,952 shares of the company’s stock worth $173,000 after buying an additional 1,316 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Arcutis Biotherapeutics by 1,291.1% in the third quarter. Jones Financial Companies Lllp now owns 7,067 shares of the company’s stock worth $124,000 after buying an additional 6,559 shares during the last quarter. Whalen Wealth Management Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the fourth quarter worth $233,000. Finally, Cookson Peirce & Co. Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the third quarter worth $188,000.

Insider Buying and Selling

In other news, insider Patrick Burnett sold 6,287 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $25.18, for a total value of $158,306.66. Following the completion of the transaction, the insider owned 121,150 shares in the company, valued at approximately $3,050,557. This represents a 4.93% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Todd Watanabe sold 37,349 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $25.18, for a total transaction of $940,447.82. Following the completion of the transaction, the insider owned 785,957 shares of the company’s stock, valued at approximately $19,790,397.26. This represents a 4.54% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 92,831 shares of company stock worth $2,295,499. Insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics Trading Up 2.5%

Arcutis Biotherapeutics stock opened at $21.17 on Friday. The business has a 50 day moving average price of $23.65 and a two-hundred day moving average price of $25.77. The company has a quick ratio of 2.99, a current ratio of 2.68 and a debt-to-equity ratio of 0.54. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of -705.43 and a beta of 1.58. Arcutis Biotherapeutics, Inc. has a 12 month low of $12.72 and a 12 month high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). The firm had revenue of $105.40 million during the quarter, compared to analyst estimates of $103.68 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. As a group, equities analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.15 EPS for the current year.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $34 price target on Arcutis Biotherapeutics while raising near-term EPS estimates for 2026 quarters, reinforcing the view that earnings could improve as ZORYVE sales scale. Article Title
• Positive Sentiment: Needham also reiterated its Buy rating with a $36 target, helping sentiment by signaling that analysts still see meaningful upside from current levels.
• Positive Sentiment: The company reported a $105.4 million quarterly revenue beat and highlighted strong ZORYVE momentum, including commercial growth and pipeline progress, which remains a key driver for investor enthusiasm. Article Title
• Neutral Sentiment: Arcutis announced inducement grants to 40 new hires, a routine equity compensation move that signals continued hiring but is not likely to materially change the stock’s near-term outlook. Article Title
• Neutral Sentiment: HC Wainwright’s mix of higher and lower out-year estimates suggests analysts remain constructive overall, but are still fine-tuning the longer-term earnings model. Article Title
• Negative Sentiment: Q1 EPS missed expectations, showing Arcutis is still spending heavily as it grows; that profitability gap could limit upside if investors focus on margins rather than sales growth. Article Title
• Negative Sentiment: Several insiders sold shares under pre-arranged 10b5-1 plans, which is routine, but clustered selling can still weigh on sentiment in the short term. Article Title

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ARQT. Needham & Company LLC restated a “buy” rating and issued a $36.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday. HC Wainwright boosted their price objective on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Friday, March 27th. TD Cowen boosted their price objective on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen cut Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.00.

Arcutis Biotherapeutics Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.